[Macrolide-resistant Mycoplasma pneumoniae: Do we know the situation in Europe?]

Area of Science:

• Microbiology
• Infectious Diseases

Context:

• Mycoplasma pneumoniae is a common cause of atypical pneumonia globally.
• Epidemic outbreaks occur every 4-7 years, with endemic circulation between outbreaks.
• Macrolides, tetracyclines, and fluoroquinolones are primary treatments.

Purpose:

• To summarize the epidemiology and clinical significance of Mycoplasma pneumoniae.
• To highlight the growing challenge of macrolide resistance.
• To emphasize the role of advanced diagnostics in managing M. pneumoniae.

Summary:

• Mycoplasma pneumoniae infections are prevalent worldwide, primarily affecting the respiratory tract and causing atypical pneumonia.
• A significant increase in macrolide resistance has been observed globally since 2000, particularly in Asia, with varying frequencies in Europe.
• Molecular and serology techniques offer high sensitivity for diagnosis and outbreak control, while macrolide resistance detection requires sequencing.

Impact:

• Informing clinicians about current treatment challenges and diagnostic options.
• Guiding public health strategies for Mycoplasma pneumoniae outbreak detection and management.
• Highlighting the need for continued surveillance of antimicrobial resistance patterns.